Chile interested in expanding cooperation with St. Petersburg Research Institute

13 September 2017

GMP News

A meeting between the representatives of Instituto de Salud Pública, Chile, and St. Petersburg Research Institute of Vaccines and Serums was held in St. Petersburg.

The Chilean side represented by Pablo Ortiz Diaz, the Managing Finance Director, showed interest in expanding the cooperation with St. Petersburg Research Institute of Vaccines and Serums in assessing the potential for the presence of Russian immunobiological products in the market of Chile and other countries of the region. At the meeting, the parties agreed to sign a framework agreement on cooperation, which would include organizing the supplies of immunobiological products, joint research and development, as well as the creation of talent pool in the area of biotechnology.

“This meeting with Chilean colleagues is an important step in the development of relations both between our countries and across the Latin America. Chile pursues a consistent policy for prevention of viral diseases in population of the country, and the authorities are closely monitoring the implementation of the National Immunization Program and selection of required drugs,” said Stanislav Uiba, the Director General of MECHNIKOV Latin American Biotechnology Institute, after the meeting.

The competencies of Instituto de Salud Pública are especially important for the Russian side because of the project for construction of MECHNIKOV Latin American Biotechnology Institute implemented by St. Petersburg Research Institute of Vaccines and Serums in Nicaragua. Among other things, the activities of the Institute will be aimed at combating dangerous and rare viral diseases in Latin America and the Caribbean.


Previous publication Next publication

Media Center

  • 21 November 2017

    Russian pharmaceutical market reaches 863 billion rubles in Q1-Q3

    According to AlphaRM, September 2017 ended with the growth in the retail segment and fall in the public segment of the pharmaceutical market compared both to the previous month (+11% and -21%, respectively) and the past year (+1% and -21%, respectively).

  • 21 November 2017

    Russian pharmaceutical industry strives for new achievements

    Over the past 8 years, since the beginning of the active implementation of the “Pharma 2020” program, the right vector of development has been set and, today, the Russian pharmaceutical industry is the fastest growing sector in the country. In 2016, the Russian pharmaceutical companies were developing at a much more dynamic pace than their foreign counterparts. In that year, their revenues amounted to 314.5 billion rubles, that is 23.7% more than in 2015. At the same time, the volume of drugs imported to the Russian market increased by 8.1% over the year to reach 493.1 billion rubles.

  • 20 November 2017

    Tweet up? Twitter move to 280 characters opens new frontiers for pharma, agency says

    Will pharma learn to love Twitter now that it’s doubled its character limit to 280? Last week, the popular social media platform announced it would offer all users twice as much space, and at least one pharma ad agency says industry marketers should be glad.

  • 20 November 2017

    Biosimilars Raise Analytical and Policy Challenges

    FDA approved seven biosimilars through October 2017, based on the agency’s now well-established “step-wise” approach for assessing analytical similarity through biological and physiochemical product characterization. Still the debate continues over biosimilar naming, interchangeability, and patent protection, as well as lingering concerns in the medical community about the safety of switching patients to new therapies.

Read more